Selinexor Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Selinexor comprises 157 peer-reviewed publications across 15 journals, 5 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Sarcoma, Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, and Leukemia, Myeloid, Acute. Most recent publication: Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial., Clin Infect Dis, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
    Tao R, Liu C, Zhang W, et al. · Oncologist · 2024
    PubMed: PMID 37616529 · NCT06966154 · Recurrence
  2. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
    Song Y, Malpica L, Cai Q, et al. · Lancet Oncol · 2024
    PubMed: PMID 38092009 · NCT06966154 · Recurrence
  3. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P, Adams S, Rugo HS, et al. · N Engl J Med · 2018
    PubMed: PMID 30345906 · NCT05035745 · Triple Negative Breast Neoplasms
  4. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T, Guglielmi C, Hagenbeek A, et al. · N Engl J Med · 1995
    PubMed: PMID 7477169 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  5. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
    Pfreundschuh M, Trümper L, Osterborg A, et al. · Lancet Oncol · 2006
    PubMed: PMID 16648042 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  6. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
    Kalakonda N, Maerevoet M, Cavallo F, et al. · Lancet Haematol · 2020
    PubMed: PMID 32589977 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  7. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D, Hawkes EA, Jack A, et al. · Lancet · 2013
    PubMed: PMID 23615461 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  8. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
    Chari A, Vogl DT, Gavriatopoulou M, et al. · N Engl J Med · 2019
    PubMed: PMID 31433920 · NCT05170789 (ESdRRMM) · Multiple Myeloma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02606461
SEAL
LiposarcomaPhase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1
From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
Phase 2 Double-blinded: Placebo2.76 Months
Phase 2 Double-blinded: Selinexor3.02 Months
NCT02606461
SEAL
LiposarcomaPhase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1
From date of randomization in the Phase 2 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
Phase 2 Open Label: Selinexor1.38 Months
NCT02606461
SEAL
LiposarcomaPhase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
Phase 3 Double-blinded: Placebo2.07 Months
Phase 3 Double-blinded: Selinexor2.83 Months
NCT02606461
SEAL
LiposarcomaPhase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1
From the date of randomization in the Phase 3 open label period until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
Phase 3 Open Label: Selinexor2.73 Months
NCT03110562
BOSTON
Multiple MyelomaSVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)
From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)
SVd Arm: Selinexor + Bortezomib + Dexamethasone13.93 Months
Vd Arm: Bortezomib + Dexamethasone9.46 Months

Publications by year

1976–2026: 157 publications.

1976
1
1983
1
1987
1
1989
1
1992
1
1995
1
1996
1
2002
1
2006
2
2007
2
2008
1
2009
4
2010
2
2011
1
2012
1
2013
6
2014
4
2015
7
2016
5
2017
12
2018
6
2019
9
2020
10
2021
25
2022
16
2023
12
2024
11
2025
9
2026
4

Publications by indication

Sarcoma (43)

  • Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study.
    Nat Commun · 2026 · PMID 41559089 · NCT04595994
  • Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents.
    Oncotarget · 2022 · PMID 30112106 · NCT04595994
  • Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas.
    Eur J Cancer · 2021 · PMID 34298376 · NCT06114004
  • Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor.
    Oncologist · 2021 · PMID 33512749 · NCT06114004
  • Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas.
    Mol Clin Oncol · 2020 · PMID 26171190 · NCT06114004

Multiple Myeloma (31)

  • Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.
    Blood Adv · 2026 · PMID 41564431 · NCT05900882
  • Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.
    Onco Targets Ther · 2025 · PMID 40496494 · NCT04941937
  • Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study).
    BMC Cancer · 2025 · PMID 39865222 · NCT05675319
  • Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
    Front Oncol · 2024 · PMID 38826786 · NCT02343042
  • Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
    Clin Lymphoma Myeloma Leuk · 2023 · PMID 37393120 · NCT02343042

Lymphoma, Large B-Cell, Diffuse (22)

  • Incidence and survival of hematological cancers among adults ages ≥75 years.
    Cancer Med · 2023 · PMID 29654631 · NCT05786989
  • Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study.
    Clin Epidemiol · 2022 · PMID 30881137 · NCT05786989
  • Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.
    Clin Cancer Res · 2022 · PMID 33785483 · NCT03147885
  • Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
    Clin Lymphoma Myeloma Leuk · 2022 · PMID 35078739 · NCT02227251
  • Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
    Clin Cancer Res · 2022 · PMID 35608822 · NCT02303392

Leukemia, Myeloid, Acute (15)

  • Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients.
    Int J Hematol · 2025 · PMID 40011351 · NCT07094464
  • TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates.
    Am Soc Clin Oncol Educ Book · 2024 · PMID 38768424 · NCT07094464
  • Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions.
    EJHaem · 2024 · PMID 38024632 · NCT07094464
  • Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.
    Blood Adv · 2024 · PMID 38096805 · NCT07094464
  • Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
    Leuk Lymphoma · 2023 · PMID 37665178 · NCT02299518

Lymphoma (8)

  • Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial.
    Clin Cancer Res · 2025 · PMID 39998852 · NCT02323880
  • Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
    Br J Haematol · 2024 · PMID 38802107 · NCT02436707
  • Selinexor for advanced hematologic malignancies.
    Leuk Lymphoma · 2021 · PMID 32536290 · NCT07002099
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
    Neuro Oncol · 2021 · PMID 34608945 · NCT07002099
  • Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
    J Blood Med · 2021 · PMID 34234609 · NCT07002099

Recurrence (7)

  • Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
    Oncologist · 2024 · PMID 37616529 · NCT06966154
  • Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
    Lancet Oncol · 2024 · PMID 38092009 · NCT06966154
  • Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.
    Science · 2024 · PMID 38900877 · NCT06966154
  • Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).
    Signal Transduct Target Ther · 2022 · PMID 34702811 · NCT06966154
  • A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Ann Hematol · 2021 · PMID 33914097 · NCT03661515

Publications by journal

Trial-results highlights

For liposarcoma, the SEAL trial (NCT02606461) evaluated progression-free survival (PFS) as per RECIST Version 1.1, defined as the time from randomization until the first date of disease progression or death due to any cause, whichever occurred first. In the Phase 2 double-blind period, the placebo arm reported a median PFS of 2.76 Months. The Selinexor arm in this period reported a median PFS of 3.02 Months. In the subsequent Phase 2 open-label period, the Selinexor arm reported a median PFS of 1.38 Months.

Continuing the SEAL trial (NCT02606461) for liposarcoma, the Phase 3 double-blind period also assessed PFS as per RECIST Version 1.1, defined as the time from randomization until the first date of disease progression or death due to any cause, whichever occurred first. The placebo arm reported a median PFS of 2.07 Months. The Selinexor arm in this Phase 3 double-blind period reported a median PFS of 2.83 Months. During the Phase 3 open-label period, the Selinexor arm reported a median PFS of 2.73 Months.

In multiple myeloma, the BOSTON trial (NCT03110562) investigated progression-free survival (PFS) as assessed by an Independent Review Committee, defined as the time from randomization until IRC-confirmed documented disease progression or death, whichever occurred first. The arm receiving Selinexor in combination with bortezomib and dexamethasone (SVd arm) reported a median PFS of 13.93 Months. The arm receiving bortezomib and dexamethasone alone (Vd arm) reported a median PFS of 9.46 Months.

All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Selinexor publications (157)

2026 (4 papers)

  1. Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.
    Yong MK, Thursky K, Crane M, et al. · Clin Infect Dis · 2026 · Derived
    PubMed: PMID 40874769 · NCT04534725 (C-SMART) · Neoplasms
  2. Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study.
    Martin-Broto J, Casado A, Marquina G, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41559089 · NCT04595994 (SeliSarc) · Sarcoma
  3. Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.
    Jin Y, Cheng X, Zhang X, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41564431 · NCT05900882 · Multiple Myeloma
  4. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.
    Gouda MA, Zarifa A, Yang Y, et al. · J Immunother Precis Oncol · 2026 · Derived
    PubMed: PMID 39816915 · NCT02419495 · Neoplasm Metastasis

2025 (9 papers)

  1. Molecular Characterization and Clinical Implications of Endometrial Cancer.
    Secord AA, Powell MA, McAlpine J, et al. · Obstet Gynecol · 2025 · Derived
    PubMed: PMID 40966692 · NCT05611931 (XPORT-EC-042) · Endometrial Neoplasms
  2. NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies.
    R Choo J, Jeraj SN, Sundar R, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 40502306 · NCT04850755
  3. Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.
    Peng L, Shan T, Zhou X, et al. · Onco Targets Ther · 2025 · Derived
    PubMed: PMID 40496494 · NCT04941937 · Multiple Myeloma
  4. Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design.
    Mascarenhas J, Maher K, Rampal R, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 39911057 · NCT04562389 (SENTRY) · Primary Myelofibrosis
  5. Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial.
    Green AL, Minard CG, Liu X, et al. · Clin Cancer Res · 2025 · Derived
    PubMed: PMID 39998852 · NCT02323880 · Lymphoma
  6. Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study).
    Glöckner A, Schönland S, Einsele H, et al. · BMC Cancer · 2025 · Derived
    PubMed: PMID 39865222 · NCT05675319 (AlloRelapseMM) · Multiple Myeloma
  7. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
    Alhalabi O, Gouda MA, Milton DR, et al. · Cancer Med · 2025 · Derived
    PubMed: PMID 39945382 · NCT02419495 · Neoplasm Metastasis
  8. Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer.
    Qin T, Wang J, Wang J, et al. · Adv Sci (Weinh) · 2025 · Background
    PubMed: PMID 39887933 · NCT07172412
  9. Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients.
    Masuda Y, Sadato D, Toya T, et al. · Int J Hematol · 2025 · Background
    PubMed: PMID 40011351 · NCT07094464 · Leukemia, Myeloid, Acute

2024 (11 papers)

  1. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
    Tao R, Liu C, Zhang W, et al. · Oncologist · 2024 · Trial result
    PubMed: PMID 37616529 · NCT06966154 · Recurrence
  2. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
    Stewart DA, Kuruvilla J, Lee D, et al. · Br J Haematol · 2024 · Trial result
    PubMed: PMID 38802107 · NCT02436707 · Lymphoma
  3. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
    Song Y, Malpica L, Cai Q, et al. · Lancet Oncol · 2024 · Trial result
    PubMed: PMID 38092009 · NCT06966154 · Recurrence
  4. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.
    Mathew D, Marmarelis ME, Foley C, et al. · Science · 2024 · Trial result
    PubMed: PMID 38900877 · NCT06966154 · Recurrence
  5. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
    White D, Schiller GJ, Madan S, et al. · Front Oncol · 2024 · Derived
    PubMed: PMID 38826786 · NCT02343042 (STOMP) · Multiple Myeloma
  6. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
    Vergote I, Perez Fidalgo A, Valabrega G, et al. · Int J Gynecol Cancer · 2024 · Derived
    PubMed: PMID 38627035 · NCT05611931 (XPORT-EC-042) · Endometrial Neoplasms
  7. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
    Makker V, Perez-Fidalgo JA, Valabrega G, et al. · Gynecol Oncol · 2024 · Derived
    PubMed: PMID 38834399 · NCT05611931 (XPORT-EC-042) · Endometrial Neoplasms
  8. TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates.
    Santini V, Stahl M, Sallman DA, et al. · Am Soc Clin Oncol Educ Book · 2024 · Background
    PubMed: PMID 38768424 · NCT07094464 · Leukemia, Myeloid, Acute
  9. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions.
    Patel SA, Cerny J, Gerber WK, et al. · EJHaem · 2024 · Background
    PubMed: PMID 38024632 · NCT07094464 · Leukemia, Myeloid, Acute
  10. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.
    Nawas MT, Kosuri S · Blood Adv · 2024 · Background
    PubMed: PMID 38096805 · NCT07094464 · Leukemia, Myeloid, Acute
  11. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
    Liu Q, Zhang J, Guo C, et al. · Cell · 2024 · Background
    PubMed: PMID 38181741 · NCT07172412

2023 (12 papers)

  1. Incidence and survival of hematological cancers among adults ages ≥75 years.
    Krok-Schoen JL, Fisher JL, Stephens JA, et al. · Cancer Med · 2023 · Trial result
    PubMed: PMID 29654631 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  2. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
    Vergote I, Pérez-Fidalgo JA, Hamilton EP, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37669480 · NCT03555422 (ENGOT-EN5) · Endometrial Neoplasms
  3. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
    Schiller GJ, Lipe BC, Bahlis NJ, et al. · Clin Lymphoma Myeloma Leuk · 2023 · Derived
    PubMed: PMID 37393120 · NCT02343042 (STOMP) · Multiple Myeloma
  4. Equecabtagene Autoleucel: First Approval.
    Keam SJ · Mol Diagn Ther · 2023 · Derived
    PubMed: PMID 37658205 · NCT05201118
  5. Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study.
    Jagannath S, Delimpasi S, Grosicki S, et al. · Clin Lymphoma Myeloma Leuk · 2023 · Derived
    PubMed: PMID 37743180 · NCT03110562 (BOSTON) · Multiple Myeloma
  6. Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
    Bhatnagar B, Zhao Q, Mims AS, et al. · Leuk Lymphoma · 2023 · Derived
    PubMed: PMID 37665178 · NCT02299518 · Leukemia, Myeloid, Acute
  7. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
    Altan M, Tu J, Milton DR, et al. · Cancer · 2023 · Derived
    PubMed: PMID 37129197 · NCT02419495 · Neoplasm Metastasis
  8. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Zavras PD, Sinanidis I, Tsakiroglou P, et al. · Int J Mol Sci · 2023 · Background
    PubMed: PMID 36902450 · NCT07094464 · Leukemia, Myeloid, Acute
  9. RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.
    Wang X, Xu J, Li Q, et al. · Cancer Lett · 2023 · Background
    PubMed: PMID 37984724 · NCT07514052 · Multiple Myeloma
  10. TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Rahmé R, Braun T, Manfredi JJ, et al. · Biomedicines · 2023 · Background
    PubMed: PMID 37189770 · NCT07094464 · Leukemia, Myeloid, Acute
  11. Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.
    Najima Y · Int J Hematol · 2023 · Background
    PubMed: PMID 37036626 · NCT07094464 · Leukemia, Myeloid, Acute
  12. Recent advances in targeted therapies in acute myeloid leukemia.
    Bhansali RS, Pratz KW, Lai C, et al. · J Hematol Oncol · 2023 · Background
    PubMed: PMID 36966300 · NCT07094464 · Leukemia, Myeloid, Acute

2022 (16 papers)

  1. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).
    Tao R, Fan L, Song Y, et al. · Signal Transduct Target Ther · 2022 · Trial result
    PubMed: PMID 34702811 · NCT06966154 · Recurrence
  2. Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study.
    Arboe B, Olsen MH, Gørløv JS, et al. · Clin Epidemiol · 2022 · Trial result
    PubMed: PMID 30881137 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  3. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
    Thein KZ, Piha-Paul SA, Tsimberidou A, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 33909232 · NCT02419495 · Neoplasm Metastasis
  4. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.
    Thein KZ, Piha-Paul SA, Tsimberidou A, et al. · Exp Hematol Oncol · 2022 · Derived
    PubMed: PMID 34965890 · NCT02419495 · Neoplasm Metastasis
  5. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
    Thein KZ, Karp DD, Tsimberidou A, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 34562230 · NCT02419495 · Neoplasm Metastasis
  6. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
    Sweet K, Bhatnagar B, Döhner H, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 34323164 · NCT02088541 (SOPRA) · Leukemia, Myeloid, Acute
  7. Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.
    Seymour EK, Khan HY, Li Y, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 33785483 · NCT03147885 · Lymphoma, Large B-Cell, Diffuse
  8. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
    Schuster M, Zijlstra J, Casasnovas RO, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 35078739 · NCT02227251 · Lymphoma, Large B-Cell, Diffuse
  9. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
    Nikolaou A, Ambavane A, Shah A, et al. · Expert Rev Hematol · 2022 · Derived
    PubMed: PMID 34465265 · NCT02336815 (STORM) · Multiple Myeloma
  10. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
    Gounder MM, Razak AA, Somaiah N, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35394800 · NCT02606461 (SEAL) · Liposarcoma
  11. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
    Delimpasi S, Mateos MV, Auner HW, et al. · Am J Hematol · 2022 · Derived
    PubMed: PMID 34882831 · NCT03110562 (BOSTON) · Multiple Myeloma
  12. Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.
    Chari A, Florendo E, Mancia IS, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 34404623 · NCT02336815 (STORM) · Multiple Myeloma
  13. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
    Stephens DM, Huang Y, Ruppert AS, et al. · Clin Cancer Res · 2022 · Background
    PubMed: PMID 35608822 · NCT02303392 · Lymphoma, Large B-Cell, Diffuse
  14. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Mishra A, Tamari R, DeZern AE, et al. · J Clin Oncol · 2022 · Background
    PubMed: PMID 35816664 · NCT07094464 · Leukemia, Myeloid, Acute
  15. Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents.
    Kashyap T, Argueta C, Unger T, et al. · Oncotarget · 2022 · Background
    PubMed: PMID 30112106 · NCT04595994 (SeliSarc) · Sarcoma
  16. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
    Bewersdorf JP, Allen C, Mirza AS, et al. · Transplant Cell Ther · 2022 · Background
    PubMed: PMID 34551341 · NCT07094464 · Leukemia, Myeloid, Acute

2021 (25 papers)

  1. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
    Wang J, Sun T, Meng Z, et al. · Cancer Lett · 2021 · Trial result
    PubMed: PMID 33493586 · NCT05975944 · Small Cell Lung Carcinoma
  2. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Harris LJ, Patel K, Martin M, et al. · Int J Mol Sci · 2021 · Trial result
    PubMed: PMID 33202794 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  3. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
    Deng M, Zhang M, Xu-Monette ZY, et al. · J Hematol Oncol · 2021 · Trial result
    PubMed: PMID 33148342 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  4. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.
    Blood · 2021 · Trial result
    PubMed: PMID 29437609 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  5. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Cazelles C, Belhadj K, Vellemans H, et al. · Leuk Lymphoma · 2021 · Trial result
    PubMed: PMID 33764240 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  6. XPO1-dependent nuclear export as a target for cancer therapy.
    Azizian NG, Li Y · J Hematol Oncol · 2021 · Trial result
    PubMed: PMID 32487143 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  7. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
    Turner JG, Cui Y, Bauer AA, et al. · Cancer Res · 2021 · Derived
    PubMed: PMID 33023948 · NCT02780609 · Multiple Myeloma
  8. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
    Tremblay G, Daniele P, Breeze J, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 34488662 · NCT02336815 (STORM) · Multiple Myeloma
  9. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
    Shah J, Shacham S, Kauffman M, et al. · Future Oncol · 2021 · Derived
    PubMed: PMID 33528286 · NCT02227251 · Lymphoma, Large B-Cell, Diffuse
  10. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
    Richard S, Chari A, Delimpasi S, et al. · Am J Hematol · 2021 · Derived
    PubMed: PMID 34062004 · NCT03110562 (BOSTON) · Multiple Myeloma
  11. Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
    Nilsson S, Stein A, Rolfo C, et al. · Curr Cancer Drug Targets · 2021 · Derived
    PubMed: PMID 32598257 · NCT02384850 (SENTINEL) · Neoplasm Metastasis
  12. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
    Mateos MV, Gavriatopoulou M, Facon T, et al. · J Hematol Oncol · 2021 · Derived
    PubMed: PMID 33849608 · NCT03110562 (BOSTON) · Multiple Myeloma
  13. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Martínez Sánchez MP, Megías-Vericat JE, Rodríguez-Veiga R, et al. · Ann Hematol · 2021 · Derived
    PubMed: PMID 33914097 · NCT03661515 (FLAGINEXOR) · Recurrence
  14. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
    Maerevoet M, Zijlstra JM, Follows G, et al. · J Hematol Oncol · 2021 · Derived
    PubMed: PMID 34271963 · NCT02227251 · Lymphoma, Large B-Cell, Diffuse
  15. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N, Hirsch C, Chai KL, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34473343 · NCT04534725 (C-SMART) · Neoplasms
  16. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.
    Bhatnagar B, Zhao Q, Mims AS, et al. · Leuk Lymphoma · 2021 · Derived
    PubMed: PMID 31545113 · NCT02093403 · Leukemia, Myeloid, Acute
  17. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Azmi AS, Khan HY, Muqbil I, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 31831564 · NCT02178436 · Pancreatic Neoplasms
  18. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
    Auner HW, Gavriatopoulou M, Delimpasi S, et al. · Am J Hematol · 2021 · Derived
    PubMed: PMID 33755235 · NCT03110562 (BOSTON) · Multiple Myeloma
  19. Selinexor for advanced hematologic malignancies.
    Walker JS, Garzon R, Lapalombella R, et al. · Leuk Lymphoma · 2021 · Background
    PubMed: PMID 32536290 · NCT07002099 · Lymphoma
  20. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
    Ostrom QT, Cioffi G, Waite K, et al. · Neuro Oncol · 2021 · Background
    PubMed: PMID 34608945 · NCT07002099 · Lymphoma
  21. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
    Neupane K, Wahab A, Masood A, et al. · J Blood Med · 2021 · Background
    PubMed: PMID 34234609 · NCT07002099 · Lymphoma
  22. Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate.
    Lurain K, Uldrick TS, Ramaswami R, et al. · Blood · 2021 · Background
    PubMed: PMID 32609814 · NCT07002099 · Lymphoma
  23. Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas.
    Kantidakis G, Litière S, Neven A, et al. · Eur J Cancer · 2021 · Background
    PubMed: PMID 34298376 · NCT06114004 (SeliSarc) · Sarcoma
  24. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.
    Gandhi MK, Hoang T, Law SC, et al. · Blood · 2021 · Background
    PubMed: PMID 33202420 · NCT07002099 · Lymphoma
  25. Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor.
    Al-Ezzi E, Gounder M, Watson G, et al. · Oncologist · 2021 · Background
    PubMed: PMID 33512749 · NCT06114004 (SeliSarc) · Sarcoma

2020 (10 papers)

  1. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Robson ME, Tung N, Conte P, et al. · Ann Oncol · 2020 · Trial result
    PubMed: PMID 30689707 · NCT05035745 · Triple Negative Breast Neoplasms
  2. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
    Kalakonda N, Maerevoet M, Cavallo F, et al. · Lancet Haematol · 2020 · Trial result
    PubMed: PMID 32589977 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  3. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
    Vergote IB, Lund B, Peen U, et al. · Gynecol Oncol · 2020 · Derived
    PubMed: PMID 31822399 · NCT02025985 (SIGN) · Endometrial Neoplasms
  4. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
    Taylor J, Mi X, Penson AV, et al. · Lancet Haematol · 2020 · Derived
    PubMed: PMID 32735836 · NCT02228525 · Myelodysplastic Syndromes
  5. A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.
    Shafique M, Ismail-Khan R, Extermann M, et al. · Oncologist · 2020 · Derived
    PubMed: PMID 30996012 · NCT02402764 · Triple Negative Breast Neoplasms
  6. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
    Jakubowiak AJ, Jasielec JK, Rosenbaum CA, et al. · Br J Haematol · 2020 · Derived
    PubMed: PMID 31124580 · NCT02199665 (SINE) · Multiple Myeloma
  7. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
    Grosicki S, Simonova M, Spicka I, et al. · Lancet · 2020 · Derived
    PubMed: PMID 33189178 · NCT03110562 (BOSTON) · Multiple Myeloma
  8. Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas.
    Sonnenblick A, Eleyan F, Peretz T, et al. · Mol Clin Oncol · 2020 · Background
    PubMed: PMID 26171190 · NCT06114004 (SeliSarc) · Sarcoma
  9. Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors-A Sarcoma Reference Center Experience.
    Sobczuk P, Teterycz P, Czarnecka AM, et al. · J Clin Med · 2020 · Background
    PubMed: PMID 33003503 · NCT06114004 (SeliSarc) · Sarcoma
  10. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.
    Houillier C, Soussain C, Ghesquières H, et al. · Neurology · 2020 · Background
    PubMed: PMID 31907289 · NCT07002099 · Lymphoma

2019 (9 papers)

  1. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH, Senapedis W, Baloglu E, et al. · Clin Lymphoma Myeloma Leuk · 2019 · Trial result
    PubMed: PMID 29610030 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  2. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
    Galon J, Bruni D · Nat Rev Drug Discov · 2019 · Trial result
    PubMed: PMID 30610226 · NCT04850755
  3. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
    Chari A, Vogl DT, Gavriatopoulou M, et al. · N Engl J Med · 2019 · Trial result
    PubMed: PMID 31433920 · NCT05170789 (ESdRRMM) · Multiple Myeloma
  4. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.
    Zhang W, Ly C, Ishizawa J, et al. · Haematologica · 2019 · Derived
    PubMed: PMID 29773601 · NCT02530476 · Recurrence
  5. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
    Wei XX, Siegel AP, Aggarwal R, et al. · Oncologist · 2019 · Derived
    PubMed: PMID 29487219 · NCT02215161
  6. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
    Wang AY, Weiner H, Green M, et al. · J Hematol Oncol · 2019 · Derived
    PubMed: PMID 29304833 · NCT02573363 · Leukemia, Myeloid, Acute
  7. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
    Vogl DT, Dingli D, Cornell RF, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29381435 · NCT02336815 (STORM) · Multiple Myeloma
  8. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
    Bahlis NJ, Sutherland H, White D, et al. · Blood · 2019 · Derived
    PubMed: PMID 30352784 · NCT02343042 (STOMP) · Multiple Myeloma
  9. Pneumatic tube systems--key to relieving the|| pressure.
    Beska J · Health Estate · 2019 · Background
    PubMed: PMID 11116598 · NCT07514052 · Multiple Myeloma

2018 (6 papers)

  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P, Adams S, Rugo HS, et al. · N Engl J Med · 2018 · Trial result
    PubMed: PMID 30345906 · NCT05035745 · Triple Negative Breast Neoplasms
  2. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
    Corno C, Stucchi S, De Cesare M, et al. · Biochem Pharmacol · 2018 · Trial result
    PubMed: PMID 29155058 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  3. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
    Martin-Broto J, Redondo A, Valverde C, et al. · Ann Oncol · 2018 · Background
    PubMed: PMID 29045512 · NCT06114004 (SeliSarc) · Sarcoma
  4. Cutaneous epithelioid malignant peripheral nerve sheath tumour: a clinicopathological analysis of 11 cases.
    Luzar B, Shanesmith R, Ramakrishnan R, et al. · Histopathology · 2018 · Background
    PubMed: PMID 26096054 · NCT06114004 (SeliSarc) · Sarcoma
  5. Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.
    Le Guellec S, Macagno N, Velasco V, et al. · Mod Pathol · 2018 · Background
    PubMed: PMID 28752843 · NCT06114004 (SeliSarc) · Sarcoma
  6. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
    Kolberg M, Bruun J, Murumägi A, et al. · Mol Oncol · 2018 · Background
    PubMed: PMID 28556483 · NCT06114004 (SeliSarc) · Sarcoma

2017 (12 papers)

  1. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
    Kwong YL, Chan TSY, Tan D, et al. · Blood · 2017 · Trial result
    PubMed: PMID 28188133 · NCT06966154 · Recurrence
  2. The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.
    Farren MR, Hennessey RC, Shakya R, et al. · Mol Cancer Ther · 2017 · Trial result
    PubMed: PMID 28148715 · NCT05170789 (ESdRRMM) · Multiple Myeloma
  3. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.
    Alexander TB, Lacayo NJ, Choi JK, et al. · J Clin Oncol · 2017 · Trial result
    PubMed: PMID 27507877 · NCT03071276 · Leukemia, Myeloid, Acute
  4. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG, Dawson JL, Grant S, et al. · J Hematol Oncol · 2017 · Derived
    PubMed: PMID 27557643 · NCT02186834 · Multiple Myeloma
  5. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
    Machlus KR, Wu SK, Vijey P, et al. · Blood · 2017 · Derived
    PubMed: PMID 28630120 · NCT01607905 · Glioblastoma
  6. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.
    Wang Z, Shi N, Naing A, et al. · Cancer Med · 2017 · Background
    PubMed: PMID 27882721 · NCT06114004 (SeliSarc) · Sarcoma
  7. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B, Strauss SJ, Whelan J, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 28882536 · NCT06114004 (SeliSarc) · Sarcoma
  8. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
    Nakayama R, Zhang YX, Czaplinski JT, et al. · Oncotarget · 2017 · Background
    PubMed: PMID 26918731 · NCT06114004 (SeliSarc) · Sarcoma
  9. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
    Martin-Broto J, Pousa AL, de Las Peñas R, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27185843 · NCT06114004 (SeliSarc) · Sarcoma
  10. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
    Kumar S, Paiva B, Anderson KC, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27511158 · NCT03732703 (MyDRUG) · Multiple Myeloma
  11. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
    Gounder MM, Zer A, Tap WD, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27458288 · NCT04519476 · Multiple Myeloma
  12. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.
    Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 26926685 · NCT04519476 · Multiple Myeloma

2016 (5 papers)

  1. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
    Kazim S, Malafa MP, Coppola D, et al. · Mol Cancer Ther · 2016 · Trial result
    PubMed: PMID 25934708 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  2. Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications.
    Khan MA, Srivastava SK, Bhardwaj A, et al. · Oncotarget · 2016 · Background
    PubMed: PMID 25970774 · NCT06114004 (SeliSarc) · Sarcoma
  3. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
    Ishizawa J, Kojima K, Hail N, et al. · Pharmacol Ther · 2016 · Background
    PubMed: PMID 26048327 · NCT06114004 (SeliSarc) · Sarcoma
  4. Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.
    Hirbe AC, Dahiya S, Miller CA, et al. · Clin Cancer Res · 2016 · Background
    PubMed: PMID 25925892 · NCT06114004 (SeliSarc) · Sarcoma
  5. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M, Cominetti D, Doldi V, et al. · Oncotarget · 2016 · Background
    PubMed: PMID 25948791 · NCT06114004 (SeliSarc) · Sarcoma

2015 (7 papers)

  1. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
    Tan DS, Bedard PL, Kuruvilla J, et al. · Cancer Discov · 2015 · Trial result
    PubMed: PMID 24743138 · NCT04850755
  2. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors.
    Zhang M, Wang Y, Jones S, et al. · Nat Genet · 2015 · Background
    PubMed: PMID 25305755 · NCT06114004 (SeliSarc) · Sarcoma
  3. A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.
    Seddon B, Scurr M, Jones RL, et al. · Clin Sarcoma Res · 2015 · Background
    PubMed: PMID 25987978 · NCT06114004 (SeliSarc) · Sarcoma
  4. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
    Lee W, Teckie S, Wiesner T, et al. · Nat Genet · 2015 · Background
    PubMed: PMID 25240281 · NCT06114004 (SeliSarc) · Sarcoma
  5. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
    Gravina GL, Tortoreto M, Mancini A, et al. · J Hematol Oncol · 2015 · Background
    PubMed: PMID 25284315 · NCT06114004 (SeliSarc) · Sarcoma
  6. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
    Gravina GL, Senapedis W, McCauley D, et al. · J Hematol Oncol · 2015 · Background
    PubMed: PMID 25476752 · NCT06114004 (SeliSarc) · Sarcoma
  7. Selective inhibitors of nuclear export (SINE) in hematological malignancies.
    Das A, Wei G, Parikh K, et al. · Exp Hematol Oncol · 2015 · Background
    PubMed: PMID 25745591 · NCT06114004 (SeliSarc) · Sarcoma

2014 (4 papers)

  1. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
    Mounier N, El Gnaoui T, Tilly H, et al. · Haematologica · 2014 · Trial result
    PubMed: PMID 23753028 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  2. Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.
    Siena L, Pace E, Ferraro M, et al. · Immunology · 2014 · Background
    PubMed: PMID 24128051 · NCT06114004 (SeliSarc) · Sarcoma
  3. Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.
    Hill R, Rabb M, Madureira PA, et al. · Cell Death Dis · 2014 · Background
    PubMed: PMID 24008735 · NCT06114004 (SeliSarc) · Sarcoma
  4. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.
    De Raedt T, Beert E, Pasmant E, et al. · Nature · 2014 · Background
    PubMed: PMID 25119042 · NCT06114004 (SeliSarc) · Sarcoma

2013 (6 papers)

  1. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D, Hawkes EA, Jack A, et al. · Lancet · 2013 · Trial result
    PubMed: PMID 23615461 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  2. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.
    An G, Xu Y, Shi L, et al. · Leuk Res · 2013 · Trial result
    PubMed: PMID 23927993 · NCT05170789 (ESdRRMM) · Multiple Myeloma
  3. Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.
    Moysan E, Bastiat G, Benoit JP, et al. · Mol Pharm · 2013 · Background
    PubMed: PMID 22978251 · NCT06114004 (SeliSarc) · Sarcoma
  4. Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy.
    Kondo S, Ueno H, Hashimoto J, et al. · BMC Cancer · 2013 · Background
    PubMed: PMID 22731825 · NCT06114004 (SeliSarc) · Sarcoma
  5. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
    Kolberg M, Høland M, Agesen TH, et al. · Neuro Oncol · 2013 · Background
    PubMed: PMID 23161774 · NCT06114004 (SeliSarc) · Sarcoma
  6. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location.
    Kamran SC, Howard SA, Shinagare AB, et al. · Eur J Surg Oncol · 2013 · Background
    PubMed: PMID 23084090 · NCT06114004 (SeliSarc) · Sarcoma

2012 (1 paper)

  1. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
    van der Graaf WT, Blay JY, Chawla SP, et al. · Lancet · 2012 · Background
    PubMed: PMID 22595799 · NCT06114004 (SeliSarc) · Sarcoma

2011 (1 paper)

  1. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
    García-Del-Muro X, López-Pousa A, Maurel J, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21606430 · NCT06114004 (SeliSarc) · Sarcoma

2010 (2 papers)

  1. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
    Gisselbrecht C, Glass B, Mounier N, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 20660832 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  2. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
    Gordon N, Kleinerman ES · Cancer Treat Res · 2010 · Background
    PubMed: PMID 20213411 · NCT06114004 (SeliSarc) · Sarcoma

2009 (4 papers)

  1. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
    Corazzelli G, Capobianco G, Arcamone M, et al. · Cancer Chemother Pharmacol · 2009 · Trial result
    PubMed: PMID 19219604 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  2. The expression of CRM1 is associated with prognosis in human osteosarcoma.
    Yao Y, Dong Y, Lin F, et al. · Oncol Rep · 2009 · Background
    PubMed: PMID 19082467 · NCT06114004 (SeliSarc) · Sarcoma
  3. CRM1-mediated nuclear export of proteins and drug resistance in cancer.
    Turner JG, Sullivan DM · Curr Med Chem · 2009 · Background
    PubMed: PMID 18991627 · NCT06114004 (SeliSarc) · Sarcoma
  4. Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells.
    Park KS, Han BG, Lee KH, et al. · Cancer Lett · 2009 · Background
    PubMed: PMID 18851895 · NCT06114004 (SeliSarc) · Sarcoma

2008 (1 paper)

  1. Targeting sarcomas: therapeutic targets and their rational.
    Ordóñez JL, Martins AS, Osuna D, et al. · Semin Diagn Pathol · 2008 · Background
    PubMed: PMID 19013896 · NCT06114004 (SeliSarc) · Sarcoma

2007 (2 papers)

  1. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
    Maki RG, Wathen JK, Patel SR, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17602081 · NCT06114004 (SeliSarc) · Sarcoma
  2. Revised response criteria for malignant lymphoma.
    Cheson BD, Pfistner B, Juweid ME, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17242396 · NCT02138786 (SIRRT)

2006 (2 papers)

  1. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
    Pfreundschuh M, Trümper L, Osterborg A, et al. · Lancet Oncol · 2006 · Trial result
    PubMed: PMID 16648042 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse
  2. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.
    Gilbert JA, Salavaggione OE, Ji Y, et al. · Clin Cancer Res · 2006 · Background
    PubMed: PMID 16551864 · NCT06114004 (SeliSarc) · Sarcoma

2002 (1 paper)

  1. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.
    Van Glabbeke M, Verweij J, Judson I, et al. · Eur J Cancer · 2002 · Background
    PubMed: PMID 11872347 · NCT06114004 (SeliSarc) · Sarcoma

1996 (1 paper)

  1. Preclinical characteristics of gemcitabine.
    Plunkett W, Huang P, Gandhi V, et al. · Anticancer Drugs · 1996 · Background
    PubMed: PMID 8718419 · NCT06114004 (SeliSarc) · Sarcoma

1995 (1 paper)

  1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T, Guglielmi C, Hagenbeek A, et al. · N Engl J Med · 1995 · Trial result
    PubMed: PMID 7477169 · NCT05786989 · Lymphoma, Large B-Cell, Diffuse

1992 (1 paper)

  1. A formula to estimate the approximate surface area if height and weight be known. 1916.
    Du Bois D, Du Bois EF · Nutrition · 1992 · Background
    PubMed: PMID 2520314 · NCT04661137 · Multiple Myeloma

1989 (1 paper)

  1. Optimal two-stage designs for phase II clinical trials.
    Simon R · Control Clin Trials · 1989 · Background
    PubMed: PMID 2702835 · NCT06114004 (SeliSarc) · Sarcoma

1987 (1 paper)

  1. Simplified calculation of body-surface area.
    Mosteller RD · N Engl J Med · 1987 · Background
    PubMed: PMID 3657876 · NCT04661137 · Multiple Myeloma

1983 (1 paper)

  1. Toxicity and response criteria of the Eastern Cooperative Oncology Group.
    Oken MM, Creech RH, Tormey DC, et al. · Am J Clin Oncol · 1983 · Background
    PubMed: PMID 7165009 · NCT04661137 · Multiple Myeloma

1976 (1 paper)

  1. Prediction of creatinine clearance from serum creatinine.
    Cockcroft DW, Gault MH · Nephron · 1976 · Background
    PubMed: PMID 1244564 · NCT04661137 · Multiple Myeloma

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).